{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T18:39:14Z","timestamp":1762022354382,"version":"build-2065373602"},"reference-count":6,"publisher":"Centers for Disease Control MMWR Office","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Morb. Mortal. Wkly. Rep."],"DOI":"10.15585\/mmwr.mm6921a3","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T14:17:23Z","timestamp":1590675443000},"page":"656-657","source":"Crossref","is-referenced-by-count":3,"title":["<i>Notes from the Field:<\/i> Impact of a Mass Drug Administration Campaign Using a Novel Three-Drug Regimen on Lymphatic Filariasis Antigenemia \u2014 American Samoa, 2019"],"prefix":"10.15585","volume":"69","author":[{"given":"Marisa A.","family":"Hast","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aifili","family":"Tufa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara A.","family":"Brant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynette","family":"Suiaunoa-Scanlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"June","family":"Vaifanua-Leo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keri","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Dodd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Sili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loretta S.","family":"Lees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly Y.","family":"Won","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fara","family":"Utu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6224","published-online":{"date-parts":[[2020,5,29]]},"reference":[{"key":"key-10.15585\/mmwr.mm6921a3-202005281016-R1","first-page":"457","article-title":"Global programme to eliminate lymphatic filariasis: progress report, 2018.","volume":"94","author":"World Health Organization","year":"2019","journal-title":"Wkly Epidemiol Rec"},{"key":"key-10.15585\/mmwr.mm6921a3-202005281016-R2","unstructured":"World Health Organization Regional Office for the Western Pacific. The PacELF way: towards the elimination of lymphatic filariasis from the Pacific, 1999\u20132005. Manila, Philippines: World Health Organization Regional Office for the Western Pacific; 2006. https:\/\/iris.wpro.who.int\/handle\/10665.1\/10966"},{"key":"key-10.15585\/mmwr.mm6921a3-202005281016-R3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s41182-017-0063-8","article-title":"Prevalence and risk factors associated with lymphatic filariasis in American Samoa after mass drug administration.","volume":"45","author":"Coutts","year":"2017","journal-title":"Trop Med Health"},{"key":"key-10.15585\/mmwr.mm6921a3-202005281016-R4","doi-asserted-by":"publisher","first-page":"e0006583","DOI":"10.1371\/journal.pntd.0006583","article-title":"Identifying residual transmission of lymphatic filariasis after mass drug administration: comparing school-based versus community-based surveillance\u2014American Samoa, 2016.","volume":"12","author":"Sheel","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"key-10.15585\/mmwr.mm6921a3-202005281016-R5","unstructured":"World Health Organization. Guideline: alternative mass drug administration regimens to eliminate lymphatic filariasis. Geneva, Switzerland: World Health Organization; 2017. https:\/\/www.who.int\/publications-detail\/9789241550161"},{"key":"key-10.15585\/mmwr.mm6921a3-202005281016-R6","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/cid\/civ882","article-title":"Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis.","volume":"62","author":"Thomsen","year":"2016","journal-title":"Clin Infect Dis"}],"container-title":["MMWR. Morbidity and Mortality Weekly Report"],"original-title":[],"deposited":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T14:17:27Z","timestamp":1590675447000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/69\/wr\/mm6921a3.htm?s_cid=mm6921a3_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,29]]},"references-count":6,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2020,5,29]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.mm6921a3","relation":{},"ISSN":["0149-2195","1545-861X"],"issn-type":[{"type":"print","value":"0149-2195"},{"type":"electronic","value":"1545-861X"}],"subject":[],"published-other":{"date-parts":[[2020,5,29]]},"published":{"date-parts":[[2020,5,29]]}}}